BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Windfall from the ongoing drug shortages and traction in gRevlimid sales in the U.S. drove 16% / 45% / 41% YoY increase in revenue / Ebitda /profit after tax in Q1 FY24 for the pharma companies under our coverage.
Gross and Ebitda margins rose 300 basis points / 440 bps YoY to 65.3% / 23.8% on an aggregate basis. While U.S. traction will likely continue for a couple of more quarters, National list of essential medicine-led price increase in India and softening of raw material prices could further sweeten the margin profile from Q2 FY24.
Cipla Ltd., Ajanta Pharma Ltd. and Abbott India Ltd. are our top picks in the pharma space.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
Colgate-Palmolive Q4 Results Review - Market Shares (Gains) Bottomed Out: ICICI Securities
May 15, 2024
Gravita India - A Capex, ESG Play; ICICI Securities Initiates Coverage With A Buy
May 09, 2024
Tatva Chintan Q4 Results Review - Revenue May Rise 25% With Expansion In Margin: ICICI Securities
May 07, 2024
Go Fashion Q4 Results Review - Demand Outlook Remains Challenging: ICICI Securities
May 06, 2024
POPULAR